Biomarin Pharmaceutical Inc (BMRN)

Liquidity ratios

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio 5.33 4.27 3.05 2.74 2.51 2.54 4.94 4.75 4.67 5.15 5.42 4.88 4.16 4.49 5.32 5.32 4.76 3.20 3.26 2.58
Quick ratio 2.96 2.39 1.79 1.55 1.45 1.46 2.98 2.93 2.98 3.25 3.39 3.03 2.54 2.82 3.49 3.45 3.07 2.24 2.17 1.53
Cash ratio 1.87 1.30 1.15 0.96 0.91 0.97 1.96 1.93 2.19 2.44 2.39 2.15 1.86 2.10 2.53 2.53 2.16 1.76 1.70 1.05

Biomarin Pharmaceutical Inc has exhibited strong liquidity ratios over the past few years. The current ratio has shown a consistent upward trend from 2.58 as of March 31, 2020, to 5.33 as of December 31, 2024. This indicates that the company has more than enough current assets to cover its current liabilities, reflecting a healthy liquidity position.

Similarly, the quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, has also demonstrated a positive trend. It increased from 1.53 on March 31, 2020, to 2.96 on December 31, 2024. This implies that Biomarin Pharmaceutical Inc can meet its short-term obligations even if inventory is excluded from its current assets.

Additionally, the cash ratio, which is the most stringent measure of liquidity as it considers only cash and cash equivalents to cover current liabilities, has also shown improvement over the years. It rose from 1.05 on March 31, 2020, to 1.87 on December 31, 2024. This suggests that the company has maintained a healthy level of cash reserves to meet its short-term obligations.

Overall, Biomarin Pharmaceutical Inc's liquidity ratios paint a positive picture, indicating that the company is well-equipped to meet its short-term financial obligations and has the capacity to fund its operations without relying heavily on external financing.

Additional liquidity measure

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash conversion cycle days 860.59 846.61 930.58 895.02 860.52 814.92 800.59 770.70 756.48 720.13 721.42 698.08 677.08 648.37 543.51 568.48 576.11 600.26 751.80 756.46

The cash conversion cycle of Biomarin Pharmaceutical Inc has fluctuated over the period from March 31, 2020, to December 31, 2024. The cash conversion cycle represents the time it takes for a company to convert its investments in inventory into cash flows from sales. A longer cash conversion cycle indicates that the company takes more time to generate cash from its operations.

Biomarin Pharmaceutical Inc's cash conversion cycle started at 756.46 days on March 31, 2020, and gradually decreased to a low of 543.51 days on June 30, 2021. This decrease indicates the company was improving its efficiency in managing its working capital during this period. However, the cash conversion cycle started to increase again, reaching 930.58 days on June 30, 2024. This increase may suggest challenges in managing inventory, collecting receivables, or paying payables efficiently.

Overall, Biomarin Pharmaceutical Inc's cash conversion cycle has shown variability, with fluctuations in the efficiency of its working capital management. Investors and analysts may further investigate the reasons behind these fluctuations to assess the company's ability to generate cash flows from its operational activities effectively.